SMO ClinPlus Co. Ltd. (301257) - Net Assets
Based on the latest financial reports, SMO ClinPlus Co. Ltd. (301257) has net assets worth CN¥1.28 Billion CNY (≈ $187.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.52 Billion ≈ $223.14 Million USD) and total liabilities (CN¥243.37 Million ≈ $35.61 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See debt-free asset ratio of SMO ClinPlus Co. Ltd. to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.28 Billion |
| % of Total Assets | 84.04% |
| Annual Growth Rate | 47.11% |
| 5-Year Change | 454.75% |
| 10-Year Change | N/A |
| Growth Volatility | 110.85 |
SMO ClinPlus Co. Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how SMO ClinPlus Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see SMO ClinPlus Co. Ltd. market capitalisation.
Annual Net Assets for SMO ClinPlus Co. Ltd. (2019–2025)
The table below shows the annual net assets of SMO ClinPlus Co. Ltd. from 2019 to 2025. Also explore SMO ClinPlus Co. Ltd. (301257) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.27 Billion ≈ $185.77 Million |
+8.21% |
| 2024-12-31 | CN¥1.17 Billion ≈ $171.67 Million |
+8.56% |
| 2023-12-31 | CN¥1.08 Billion ≈ $158.13 Million |
+13.51% |
| 2022-12-31 | CN¥951.97 Million ≈ $139.30 Million |
+315.99% |
| 2021-12-31 | CN¥228.84 Million ≈ $33.49 Million |
+38.73% |
| 2020-12-31 | CN¥164.96 Million ≈ $24.14 Million |
+31.76% |
| 2019-12-31 | CN¥125.19 Million ≈ $18.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SMO ClinPlus Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 696.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥503.53 Million | 39.66% |
| Other Components | CN¥765.98 Million | 60.34% |
| Total Equity | CN¥1.27 Billion | 100.00% |
SMO ClinPlus Co. Ltd. Competitors by Market Cap
The table below lists competitors of SMO ClinPlus Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xinjiang Tianshan Animal Husbandry Bio-engineering Co Ltd
SHE:300313
|
$458.94 Million |
|
Wild Bunch AG
F:WBAH
|
$459.06 Million |
|
Shenzhen Emperor Technology Co Ltd
SHE:300546
|
$459.08 Million |
|
BlackRock Core Bond Closed Fund
NYSE:BHK
|
$459.33 Million |
|
Hunan Resun Co Ltd
SHE:001218
|
$458.70 Million |
|
Shanghai Yahong Moulding Co Ltd
SHG:603159
|
$458.69 Million |
|
Jinlong Machinery Electronic
SHE:300032
|
$458.36 Million |
|
Zhongrui Co Ltd
SHE:301587
|
$458.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SMO ClinPlus Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,173,140,831 to 1,269,504,969, a change of 96,364,138 (8.2%).
- Net income of 109,638,075 contributed positively to equity growth.
- Dividend payments of 13,322,578 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥109.64 Million | +8.64% |
| Dividends Paid | CN¥13.32 Million | -1.05% |
| Other Changes | CN¥48.64K | +0.0% |
| Total Change | CN¥- | 8.21% |
Book Value vs Market Value Analysis
This analysis compares SMO ClinPlus Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.26x to 2.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥2.78 | CN¥39.68 | x |
| 2020-12-31 | CN¥2.82 | CN¥39.68 | x |
| 2021-12-31 | CN¥3.91 | CN¥39.68 | x |
| 2022-12-31 | CN¥12.01 | CN¥39.68 | x |
| 2023-12-31 | CN¥13.59 | CN¥39.68 | x |
| 2024-12-31 | CN¥14.76 | CN¥39.68 | x |
| 2025-12-31 | CN¥16.07 | CN¥39.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SMO ClinPlus Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.64%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.01%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.22x
- Recent ROE (8.64%) is below the historical average (18.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 41.82% | 17.25% | 1.50x | 1.61x | CN¥39.84 Million |
| 2020 | 21.41% | 10.53% | 1.15x | 1.77x | CN¥18.82 Million |
| 2021 | 25.24% | 11.49% | 1.24x | 1.77x | CN¥34.88 Million |
| 2022 | 7.61% | 12.35% | 0.51x | 1.22x | CN¥-22.79 Million |
| 2023 | 12.47% | 17.73% | 0.56x | 1.26x | CN¥26.67 Million |
| 2024 | 9.07% | 13.24% | 0.56x | 1.22x | CN¥-10.88 Million |
| 2025 | 8.64% | 13.01% | 0.55x | 1.22x | CN¥-17.31 Million |
Industry Comparison
This section compares SMO ClinPlus Co. Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,801,480,333
- Average return on equity (ROE) among peers: 24.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SMO ClinPlus Co. Ltd. (301257) | CN¥1.28 Billion | 41.82% | 0.19x | $458.74 Million |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $468.17 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.74 Billion |
| Hangzhou Tigermed Consulting (300347) | $24.06 Billion | 1.68% | 0.19x | $6.20 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $2.91 Billion | 13.92% | 0.48x | $978.07 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $533.70 Million |
| Maccura Biotechnology Co Ltd (300463) | $442.98 Million | 35.71% | 0.42x | $803.41 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $413.71 Million | 15.76% | 0.19x | $558.16 Million |
| BGI Genomics Co Ltd (300676) | $9.44 Billion | 15.48% | 0.51x | $2.43 Billion |
| Amoy Diagnostics Co Ltd (300685) | $756.74 Million | 16.75% | 0.08x | $1.04 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $130.79 Million | 64.49% | 1.52x | $644.10 Million |
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research and development in pharmaceuticals, medical devices, and health-related products in China. It offers clinical trial site management organization services to pharmaceuticals, medical devices, CRO companies, etc. The company offers preliminary modeling and preparation plans, trial site initiation, on-site execution, and project man… Read more